Nothing is Better Than Sigilon Therapeutics Inc. (SGTX) stock at the moment

Sigilon Therapeutics Inc. (NASDAQ: SGTX) stock fell -5.31% on Monday to $0.70 against a previous-day closing price of $0.74. With 0.56 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.23 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.8085 whereas the lowest price it dropped to was $0.6900. The 52-week range on SGTX shows that it touched its highest point at $2.09 and its lowest point at $0.29 during that stretch. It currently has a 1-year price target of $3.50.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SGTX was up-trending over the past week, with a rise of 52.22%, but this was up by 125.00% over a month. Three-month performance surged to 48.98% while six-month performance fell -6.66%. The stock lost -63.34% in the past year, while it has gained 100.06% so far this year. A look at the trailing 12-month EPS for SGTX yields -1.69 with Next year EPS estimates of -1.28. For the next quarter, that number is -0.38. This implies an EPS growth rate of -39.80% for this year and 14.70% for next year.

Float and Shares Shorts:

At present, 32.40 million SGTX shares are outstanding with a float of 28.13 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.13 million, which was 0.39% higher than short shares on Sep 14, 2022. In addition to Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA as the firm’s Pres, CEO & Director, Dr. Daniel G. Anderson Ph.D. serves as its Co-Founder & Member of Scientific Advisory Board.

Institutional Ownership:

Through their ownership of 52.74% of SGTX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 6.91% of SGTX, in contrast to 11.04% held by mutual funds. Shares owned by individuals account for 0.31%. As the largest shareholder in SGTX with 4.58% of the stake, Canada Pension Plan Investment Bo holds 1,485,185 shares worth 1,485,185. A second-largest stockholder of SGTX, Fidelity Management & Research Co, holds 1,063,300 shares, controlling over 3.28% of the firm’s shares. BlackRock Advisors LLC is the third largest shareholder in SGTX, holding 916,719 shares or 2.82% stake. With a 4.58% stake in SGTX, the Canada Pension Plan is the largest stakeholder. A total of 1,485,000 shares are owned by the mutual fund manager. The BlackRock Health Sciences Trust I, which owns about 1.74% of SGTX stock, is the second-largest Mutual Fund holder. It holds 564,538 shares valued at 0.2 million. Fidelity Growth Company Fund holds 1.18% of the stake in SGTX, owning 383,507 shares worth 0.13 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SGTX since 5 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SGTX analysts setting a high price target of $7.00 and a low target of $0.50, the average target price over the next 12 months is $3.50. Based on these targets, SGTX could surge 900.0% to reach the target high and fall by -28.57% to reach the target low. Reaching the average price target will result in a growth of 400.0% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. SGTX will report FY 2022 earnings on 03/12/2024. Analysts have provided yearly estimates in a range of -$1.38 being high and -$1.72 being low. For SGTX, this leads to a yearly average estimate of -$1.50. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Sigilon Therapeutics Inc. surprised analysts by $0.15 when it reported -$0.27 EPS against a consensus estimate of -$0.42. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.25 and the low estimate is -$0.66. The average estimate for the next quarter is thus -$0.38.

Summary of Insider Activity:

Insiders traded SGTX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *